Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

Publisher Name :
Date: 01-Oct-2016
No. of pages: 696

"Delivery of this report will take 1-3 days after purchase."

The Global Cancer Diagnostics Partnering 2010-2016 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer diagnostics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer diagnostics partnering contract documents

Top cancer diagnostics deals by value

This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,170 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.

Key benefits

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Cancer Diagnostics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies

Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies

Identify most active Cancer Diagnostics dealmakers since 2010

Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Diagnostics trends and structure of deals entered into by leading companies worldwide.

Cancer Diagnostics Partnering Terms and Agreements includes:

Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2010

Analysis of Cancer Diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Cancer Diagnostics deals

Access to Cancer Diagnostics contract documents

Leading Cancer Diagnostics deals by value since 2010

Most active Cancer Diagnostics dealmakers since 2010

In Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,170 Cancer Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Cancer Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Diagnostics dealmaking
2.1. Introduction
2.2. Cancer Diagnostics partnering over the years
2.3. Most active Cancer Diagnostics dealmakers
2.4. Cancer Diagnostics partnering by deal type
2.5. Cancer Diagnostics partnering by therapy area
2.6. Deal terms for Cancer Diagnostics partnering
2.6.1 Cancer Diagnostics partnering headline values
2.6.2 Cancer Diagnostics deal upfront payments7
2.6.3 Cancer Diagnostics deal milestone payments
2.6.4 Cancer Diagnostics royalty rates

Chapter 3 - Leading Cancer Diagnostics deals
3.1. Introduction
3.2. Top Cancer Diagnostics deals by value

Chapter 4 - Most active Cancer Diagnostics dealmakers
4.1. Introduction
4.2. Most active Cancer Diagnostics dealmakers
4.3. Most active Cancer Diagnostics partnering company profiles

Chapter 5 - Cancer Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Cancer Diagnostics contracts dealmaking directory

Chapter 6 - Cancer Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Cancer Diagnostics deals by company A-Z
Appendix 2 - Cancer Diagnostics deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Cancer Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Cancer Diagnostics deals by therapy area
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Cancer Diagnostics partnering since 2010
Figure 2: Active Cancer Diagnostics dealmaking activity- 2010 to 2016
Figure 3: Cancer Diagnostics partnering by deal type since 2010
Figure 4: Cancer Diagnostics partnering by disease type since 2010
Figure 5: Cancer Diagnostics deals with a headline value
Figure 6: Cancer Diagnostics deals with an upfront value
Figure 7: Cancer Diagnostics deals with a milestone value
Figure 8: Cancer Diagnostics deals with a royalty rate value
Figure 9: Top Cancer Diagnostics deals by value since 2010
Figure 10: Most active Cancer Diagnostics dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • 2017 Asia-Pacific Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities
    Published: 16-Feb-2017        Price: US 14500 Onwards        Pages: 1450
    This new 17-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years. The report provides granular market segmentation analysis and f......
  • 2017 Europe Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities
    Published: 16-Feb-2017        Price: US 45000 Onwards        Pages: 935
    This new 31-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years. The report provides granular market segmentation analysis and f......
  • 2017 Latin America Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities
    Published: 16-Feb-2017        Price: US 7850 Onwards        Pages: 550
    This new 7-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years. The report provides granular market segmentation analysis and fo......
  • 2017 Middle East Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities
    Published: 16-Feb-2017        Price: US 9850 Onwards        Pages: 530
    This new 11-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years. The report provides granular market segmentation analysis and f......
  • 2017 North America Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities
    Published: 16-Feb-2017        Price: US 10500 Onwards        Pages: 630
    This new 3-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years. The report provides granular market segmentation analysis and fo......
  • Global Cervical Cancer Screening Market & Patients, By Test Type (Pap Smear, HPV DNA, VIA) Forecast
    Published: 07-Feb-2017        Price: US 1990 Onwards        Pages: 238
    Global Cervical Market is expected to be close to US$ 7 Billion by 2020. North America controls almost 50 percent Cervical Cancer Market. United States and Japan together makes more than 50 percent market share. In Europe region, United Kingdom and France are other top two leading countries in this market place. Asia has highest share in cervical cancer screening population. Indonesia, China and India are top three countries having largest cervical cancer test population in Asia. In the study......
  • The Top 100 Developers Of Cancer In-Vitro Diagnostics Tests
    Published: 06-Feb-2017        Price: US 1109 Onwards        Pages: 180
    Did you know? In addition to developing novel diagnostics independently, Biodesix, Inc. partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents. Epic Sciences’ No Cell Left Behind® technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Arbor Vita Corporatio......
  • 2017-2021 Cancer Diagnostics Market: US, Europe, Japan--Country Segment Volume and Sales Forecasts, Laboratory Universe
    Published: 24-Jan-2017        Price: US 2850 Onwards        Pages: 11
    This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as well as ten-year test volume and sales forecasts by country.Contains 11 pages and 3 tables......
  • 2017-2021 Tumor Marker Testing Market: US, Europe, Japan--Strategic Profiles of Leading Cancer Diagnostic Reagent and Instrument Suppliers, Country Volume and Sales Forecasts
    Published: 24-Jan-2017        Price: US 3850 Onwards        Pages: 104
    This report provides estimates of the number of laboratories performing tumor marker assays, as well as test volume and sales forecasts by country.The report also presents strategic analyses of leading current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.Contains 104 pages an......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs